Literature DB >> 22234631

Curative strategies for liver metastases from colorectal cancer: a review.

Nicholas Zdenkowski1, Stanley Chen, Andre van der Westhuizen, Stephen Ackland.   

Abstract

Colorectal cancer is a very common malignancy and frequently manifests with liver metastases, often without other systemic disease. Margin-negative (R0) resection of limited metastatic disease, in conjunction with systemic antineoplastic agents, is the primary treatment strategy, leading to long survival times for appropriately selected patients. There is debate over whether the primary tumor and secondaries should be removed at the same time or in a staged manner. Chemotherapy is effective in converting some unresectable liver metastases into resectable disease, with a correspondingly better survival outcome. However, the ideal chemotherapy with or without biological agents and when it should be administered in the course of treatment are uncertain. The role of neoadjuvant chemotherapy in initially resectable liver metastases is controversial. Local delivery of chemotherapy, with and without surgery, can lead to longer disease-free survival times, but it is not routinely used with curative intent. This review focuses on methods to maximize the disease-free survival interval using chemotherapy, surgery, and local methods.

Entities:  

Mesh:

Year:  2012        PMID: 22234631      PMCID: PMC3286169          DOI: 10.1634/theoncologist.2011-0300

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  80 in total

1.  The blood supply of neoplasms in the liver.

Authors:  C BREEDIS; G YOUNG
Journal:  Am J Pathol       Date:  1954 Sep-Oct       Impact factor: 4.307

2.  A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

Authors:  M Ychou; W Hohenberger; S Thezenas; M Navarro; J Maurel; C Bokemeyer; E Shacham-Shmueli; F Rivera; C Kwok-Keung Choi; A Santoro
Journal:  Ann Oncol       Date:  2009-06-30       Impact factor: 32.976

3.  Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

Authors:  M Lorenz; H H Müller; H Schramm; H J Gassel; H G Rau; K Ridwelski; J Hauss; R Stieger; K W Jauch; W O Bechstein; A Encke
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

Review 4.  Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.

Authors:  James M Cleary; Kenneth T Tanabe; Gregory Y Lauwers; Andrew X Zhu
Journal:  Oncologist       Date:  2009-10-30

5.  Repeat hepatectomy for colorectal liver metastases.

Authors:  R Adam; H Bismuth; D Castaing; F Waechter; F Navarro; A Abascal; P Majno; L Engerran
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

6.  A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver.

Authors:  L D Wagman; M M Kemeny; L Leong; J J Terz; L R Hill; J D Beatty; W A Kokal; D U Riihimaki
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

7.  Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases.

Authors:  Kuniya Tanaka; Hideki Takakura; Kazuhisa Takeda; Kenichi Matsuo; Yasuhiko Nagano; Itaru Endo
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

8.  Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

Authors:  Alberto Sobrero; Stephen Ackland; Stephen Clarke; Ramón Perez-Carrión; Silvana Chiara; Silvia Chiara; John Gapski; Paul Mainwaring; Bernd Langer; Scott Young
Journal:  Oncology       Date:  2009-07-23       Impact factor: 2.935

9.  Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.

Authors:  H Bismuth; R Adam; F Lévi; C Farabos; F Waechter; D Castaing; P Majno; L Engerran
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

10.  Resection versus resection combined with adjuvant pre- and post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A new look at an old problem.

Authors:  N J Lygidakis; N Ziras; J Parissis
Journal:  Hepatogastroenterology       Date:  1995-04
View more
  5 in total

Review 1.  Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.

Authors:  Reza Mirnezami; Brendan J Moran; Kate Harvey; Tom Cecil; Kandiah Chandrakumaran; Norman Carr; Faheez Mohamed; Alexander H Mirnezami
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

2.  Management of potentially resectable colorectal cancer liver metastases.

Authors:  Fausto Meriggi; Paola Bertocchi; Alberto Zaniboni
Journal:  World J Gastrointest Surg       Date:  2013-05-27

3.  Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?

Authors:  K Kataoka; A Kanazawa; S Iwamoto; T Kato; A Nakajima; A Arimoto
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

4.  Macrophages mediate colon carcinoma cell adhesion in the rat liver after exposure to lipopolysaccharide.

Authors:  Nuray Gül; Simran Grewal; Marijn Bögels; Gerben J van der Bij; Malika M A Koppes; Steven J Oosterling; Donna M Fluitsma; Kees A Hoeben; Robert H J Beelen; Marjolein van Egmond
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

Review 5.  Liver-specific agents for contrast-enhanced MRI: role in oncological imaging.

Authors:  Yee Liang Thian; Angela M Riddell; Dow-Mu Koh
Journal:  Cancer Imaging       Date:  2013-12-30       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.